Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Encycle Therapeutics Inc.

www.encycletherapeutics.com

Latest From Encycle Therapeutics Inc.

Zealand Pharma Preps Pipeline For Catalyst-Filled 2020

Zealand Pharma’s recently installed CEO says it is building US operations to prepare for four potential approvals there in 2020, with commercial launches starting in 2021, its first ever.

Companies Research & Development

Deal Watch: Gilead Hopes Glympse’s Synthetic Biomarkers Can Optimize NASH Trials

Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.

Deals Business Strategies

Buying Encycle Gives Zealand Its First External Asset

Acquiring Encycle Therapeutics brings Zealand Pharma a promising IBD asset and expands the breadth of its peptide discovery platform.

Deals Gastrointestinal

Venture Funding Deals, November 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Encycle Therapeutics Inc.
  • Senior Management
  • Jeffrey Coull, PhD, Pres. & CEO
    Andrew L Roughton, PhD, VP, Discovery & Ops.
  • Contact Info
  • Encycle Therapeutics Inc.
    Phone: (647) 258-4500
    101 College St.
    Ste. 314
    Toronto, M5G 1L7
    Canada
UsernamePublicRestriction

Register